Medical Condition News

RSS

Switching off a single gene converts human gastrointestinal cells into insulin-producing cells

By switching off a single gene, scientists at Columbia University's Naomi Berrie Diabetes Center have converted human gastrointestinal cells into insulin-producing cells, demonstrating in principle that a drug could retrain cells inside a person's GI tract to produce insulin.

30 Jun 2014

EMA accepts for review Merck’s pembrolizumab MAA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced the European Medicines Agency (EMA) has accepted for review a Marketing Authorization Application (MAA) for pembrolizumab (MK-3475), the company's investigational anti-PD-1 antibody, for the treatment of advanced melanoma.

30 Jun 2014

Genervon generates biomarker data for its Phase 2a clinical trial for ALS

Genervon Biopharmaceuticals LLC ("Genervon") today announced that it has analyzed and generated a Biomarker Data Report for its recent Phase 2a clinical trial for ALS disease modification.

30 Jun 2014

Helsinn Group grants GEN Ilaç anamorelin rights for Turkey

Helsinn Group, the company focused on building quality cancer care, today announces that rights to anamorelin, its innovative ghrelin receptor agonist, have been granted in Turkey to GEN Ilaç.

30 Jun 2014

Amyotrophic lateral sclerosis in veterans: an interview with Milan Michael Karol, The Robert Packard Center for ALS Research at Johns Hopkins

ALS stands for Amyotrophic Lateral Sclerosis, better known as “Lou Gehrig’s Disease”. It is a progressive neurodegenerative disease characterized by the death of motor neurons in the brain and spinal cord.

30 Jun 2014

Novel method to measure neuron response to transcranial magnetic stimulation of the brain

Engineers and neuroscientists at Duke University have developed a method to measure the response of an individual neuron to transcranial magnetic stimulation (TMS) of the brain. The advance will help researchers understand the underlying physiological effects of TMS -- a procedure used to treat psychiatric disorders -- and optimize its use as a therapeutic treatment.

30 Jun 2014

Modified classification system finds over one-third of knee replacements as inappropriate

New research reports that more than one third of total knee replacements in the U.S. were classified as "inappropriate" using a patient classification system developed and validated in Spain. The study, published in Arthritis & Rheumatology, a journal of the American College of Rheumatology (ACR), highlights the need for consensus on patient selection criteria among U.S. medical professionals treating those with the potential need of knee replacement surgery.

30 Jun 2014

Light-sensitive molecule enables noninvasive silencing of neurons

Optogenetics, a technology that allows scientists to control brain activity by shining light on neurons, relies on light-sensitive proteins that can suppress or stimulate electrical signals within cells. This technique requires a light source to be implanted in the brain, where it can reach the cells to be controlled.

30 Jun 2014

Novel method triples length of time organs can be preserved for transplantation

A system developed by investigators at the Massachusetts General Hospital (MGH) Center for Engineering in Medicine allowed successful transplantation of rat livers after preservation for as long as four days, more than tripling the length of time organs currently can be preserved.

30 Jun 2014

Phase III TAS-102 study for metastatic colorectal cancer shows improved survival

The new combination agent TAS-102 is able to improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory to standard therapies, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona.

30 Jun 2014

Increasing clearance of ALS misfolded protein from neurons improves their survival

In work supported by The ALS Association, researchers have shown that increasing the clearance of misfolded protein from neurons improves their survival. The study was published today in the journal Nature Chemical Biology.

30 Jun 2014

patients with KRAS wild-type MCRC can benefit from Cetuximab Or Bevacizumab With Combi Chemo Equivalent For patients with KRAS wild-type MCRC

For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona.

30 Jun 2014

Single gene defines difference between aggressive and non-aggressive forms of thymoma

For a rare form of cancer called thymoma, researchers have discovered a single gene defining the difference between a fast-growing tumor requiring aggressive treatment and a slow-growing tumor that doesn't require extensive therapy.

30 Jun 2014

MedicAlert Foundation announces free medical IDs for individuals living with Malignant Hyperthermia

MedicAlert Foundation is pleased to announce that individuals living with Malignant Hyperthermia (MH) are now eligible to receive free medical IDs and live 24/7 emergency response services as the result of a grant obtained through the Sandi Ida Glickstein Fund at the Malignant Hyperthermia Association of the United States.

28 Jun 2014

Taiho Oncology presents TAS-102 Phase III RECOURSE trial results in mCRC patients

Taiho Oncology, Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), announced today detailed findings from its global Phase III RECOURSE trial of TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), an oral combination anticancer drug.

28 Jun 2014

BRI to present clinical-stage product data at International Symposium on Pediatric Neuro-Oncology

The Burzynski Research Institute, Inc. (BRI) announced today that it will present data on two of the Company's clinical-stage product candidates, Antineoplaston A10 injections (Atengenal®) and Antineoplaston AS2-1 injections (Astugenal®), at the 16th International Symposium on Pediatric Neuro-Oncology held in Singapore from June 28, 2014 to July 2, 2014.

28 Jun 2014

Psychostimulant increases risk of cardiovascular events in children with ADHD

Psychostimulant use to treat children and adolescents with attention-deficit/hyperactivity disorder (ADHD) is increasing worldwide, and the evaluation of the cardiovascular safety of stimulant medication used in treatment has been a recent topic of concern.

28 Jun 2014

CNIO researchers identify over 40 genes that predict aggressiveness of melanoma

Researchers from the Spanish National Cancer Research Centre have discovered more than 40 genes that predict the level of aggressiveness of melanoma and that distinguish it from other cancers with a poor prognosis. The discovery, published in Cancer Cell, will help to identify unique aspects of melanoma that could contribute to determine the risk of developing metastasis in patients with this disease.

28 Jun 2014

Targeting ASIC-related neurotransmission may lead to new therapies for treating drug addiction

University of Iowa researchers have discovered a new form of neurotransmission that influences the long-lasting memory created by addictive drugs, like cocaine and opioids, and the subsequent craving for these drugs of abuse. Loss of this type of neurotransmission creates changes in brains cells that resemble the changes caused by drug addiction.

28 Jun 2014

Study shows caregivers' allergy perceptions are not always accurate

It's tough being the parent of a child with food allergies. Constant vigilance is needed for everything your child eats, when a single food item containing a hidden ingredient can be fatal.

28 Jun 2014

Medical Condition News

Switching off a single gene converts human gastrointestinal cells into insulin-producing cells

EMA accepts for review Merck’s pembrolizumab MAA for treatment of advanced melanoma

Genervon generates biomarker data for its Phase 2a clinical trial for ALS

Helsinn Group grants GEN Ilaç anamorelin rights for Turkey

Amyotrophic lateral sclerosis in veterans: an interview with Milan Michael Karol, The Robert Packard Center for ALS Research at Johns Hopkins

Novel method to measure neuron response to transcranial magnetic stimulation of the brain

Modified classification system finds over one-third of knee replacements as inappropriate

Light-sensitive molecule enables noninvasive silencing of neurons

Novel method triples length of time organs can be preserved for transplantation

Phase III TAS-102 study for metastatic colorectal cancer shows improved survival

Increasing clearance of ALS misfolded protein from neurons improves their survival

patients with KRAS wild-type MCRC can benefit from Cetuximab Or Bevacizumab With Combi Chemo Equivalent For patients with KRAS wild-type MCRC

Single gene defines difference between aggressive and non-aggressive forms of thymoma

MedicAlert Foundation announces free medical IDs for individuals living with Malignant Hyperthermia

Taiho Oncology presents TAS-102 Phase III RECOURSE trial results in mCRC patients

BRI to present clinical-stage product data at International Symposium on Pediatric Neuro-Oncology

Psychostimulant increases risk of cardiovascular events in children with ADHD

CNIO researchers identify over 40 genes that predict aggressiveness of melanoma

Targeting ASIC-related neurotransmission may lead to new therapies for treating drug addiction

Study shows caregivers' allergy perceptions are not always accurate

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News